SBC Medical Group Holdings Inc., the Japanese owner and operator of a chain of aesthetic medical clinics, has officially entered the U.S. market through the completion of a strategic investment in OrangeTwist, a U.S.-based medspa chain. This investment represents the initial step in SBC's full-scale strategic expansion within the United States, leveraging a partnership model focused on joint operations and synergy between the two companies' networks in the U.S. and Asia. OrangeTwist operates 24 locations across six U.S. states, specializing in non-invasive aesthetic treatments including injectables, energy-based therapies, and regenerative procedures.
SBC cited OrangeTwist's advanced management system, which integrates procurement, clinical workflows, and real-time performance tracking, as a key factor providing operational consistency and supporting scalable growth. Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings, stated that OrangeTwist has solidified its leadership in the U.S. market by consistently delivering exceptional quality and outstanding client experiences in non-invasive aesthetic medicine. The companies plan to collaborate on selling each other's services and products in their respective markets and to develop new beauty products and services jointly.
This deal initiates the first phase of SBC's multiyear roadmap to establish a leading position in the medical aesthetics and wellness market through international expansion. The U.S. market is a strategic priority, with the medical aesthetics industry projected to grow from $34 billion to $48 billion by 2030, according to SBC. Drivers include demand for low-risk, minimal-downtime treatments like injectables and laser therapies, alongside demographic trends such as an aging population. During 2026, SBC plans additional strategic investments and partnerships in the U.S. and Southeast Asia, following a similar model to its recent e-consulting agreement with BLEZ ASIA Co. Ltd. in Thailand.
The partnership with BLEZ ASIA, which operates over 20 pharmacies and clinics, involves SBC providing management support for a new dermatology-focused clinic in Bangkok. This agreement is described as a key component of SBC's broader Asia expansion strategy. Phase two of SBC's plan, slated for 2027 and 2028, will focus on select acquisitions and joint ventures to accelerate growth, while phase three, beginning in 2029, aims for leadership positions in the U.S., Southeast Asia, and other key markets. Robert Settembro, CEO of OrangeTwist, stated that this next chapter allows them to bring exceptional aesthetic experiences to more communities while leveraging SBC's global expertise. The original announcement of this strategic move was published on Benzinga.
